Recent News

• 10.13.2025 - Treatment with PBGENE-DMD results in durable improvements in muscle function over time through increased dystrophin expression and dystrophin-positive cells
• 10.07.2025 - High-efficiency homology-directed insertion into the genome using the engineered homing endonuclease ARCUS
• 09.30.2025 - Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
• 09.30.2025 - Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
• 09.12.2025 - Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
• 09.12.2025 - Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
• 09.12.2025 - PBGENE-HBV Chronic Hepatitis B Program
• 09.08.2025 - Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
• 09.08.2025 - Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
• 08.07.2025 - Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 09.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - 8-K Current report
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - EX-99.1 EX-99.1